Dashboard
1
Poor Management Efficiency with a low ROCE of 7.80%
- The company has been able to generate a Return on Capital Employed (avg) of 7.80% signifying low profitability per unit of total capital (equity and debt)
2
Poor long term growth as Net Sales has grown by an annual rate of 3.08% and Operating profit at 5.19% over the last 5 years
3
Flat results in Mar 25
4
With ROE of 4.44%, it has a fair valuation with a 0.76 Price to Book Value
5
Market Beating performance in long term as well as near term
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
19.36%
0%
19.36%
6 Months
14.64%
0%
14.64%
1 Year
25.79%
0%
25.79%
2 Years
-1.9%
0%
-1.9%
3 Years
1.02%
0%
1.02%
4 Years
20.57%
0%
20.57%
5 Years
39.02%
0%
39.02%
Sichuan Goldstone Asia Pharmaceutical, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
3.08%
EBIT Growth (5y)
5.19%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.09
Sales to Capital Employed (avg)
0.46
Tax Ratio
21.22%
Dividend Payout Ratio
30.21%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
7.80%
ROE (avg)
5.07%
Valuation key factors
Factor
Value
P/E Ratio
17
Industry P/E
Price to Book Value
0.76
EV to EBIT
12.37
EV to EBITDA
6.93
EV to Capital Employed
0.73
EV to Sales
1.56
PEG Ratio
0.32
Dividend Yield
0.73%
ROCE (Latest)
5.94%
ROE (Latest)
4.44%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
195.70
286.30
-31.65%
Operating Profit (PBDIT) excl Other Income
26.00
97.90
-73.44%
Interest
0.40
0.30
33.33%
Exceptional Items
1.50
1.40
7.14%
Consolidate Net Profit
2.20
62.10
-96.46%
Operating Profit Margin (Excl OI)
-2.20%
249.70%
-25.19%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -31.65% vs -15.15% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -96.46% vs 89.91% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,080.80
1,186.20
-8.89%
Operating Profit (PBDIT) excl Other Income
231.20
340.70
-32.14%
Interest
1.50
3.30
-54.55%
Exceptional Items
-0.30
-68.60
99.56%
Consolidate Net Profit
88.60
120.70
-26.59%
Operating Profit Margin (Excl OI)
115.30%
205.90%
-9.06%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -8.89% vs -3.06% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -26.59% vs -43.33% in Dec 2023
About Sichuan Goldstone Asia Pharmaceutical, Inc. 
Sichuan Goldstone Asia Pharmaceutical, Inc.
Miscellaneous
No Details Available.
Company Coordinates 
No Company Details Available






